Dong Wei

Dong Wei has over 20 years of experience in the pharmaceutical industry. Dong is currently the Head of Bioanalysis at ReNAgade Therapeutics, a position they have held since October 2021. Before that, they worked at Takeda Oncology as the Associate Director of Bioanalytical and Biomarker, DMPK from 2017 to 2021. From 2005 to 2017, they were a Principal Scientist at Biogen, specializing in Biomarker & DMPK. Prior to that, they served as an Investigator at Novartis from 2004 to 2005 and a Senior Scientist at Cantata Pharmaceuticals from 2002 to 2004. Dong started their career at ArQule as a Senior Scientist in Analytical & ADME from 1999 to 2002. Overall, Dong Wei has extensive experience in bioanalysis, biomarker research, and drug metabolism and pharmacokinetics.

Dong Wei received a Ph.D. in Analytical Chemistry from the University of Maryland Baltimore County in the years 1996 to 1999. Prior to this, they obtained a B.S. in Chemistry from Fudan University and an M.S. in Organic Chemistry from the Shanghai Institute of Organic Chemistry. No specific start or end years were provided for the undergraduate and master's degrees.